<DOC>
	<DOCNO>NCT00003160</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving drug different way may kill tumor cell . PURPOSE : Phase II trial study effectiveness paclitaxel treat woman stage III stage IV ovarian cancer refractory paclitaxel platinum-based regimen .</brief_summary>
	<brief_title>Weekly Infusions Paclitaxel Treating Women With Stage III Stage IV Ovarian Cancer Refractory Paclitaxel Platinum</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate paclitaxel give weekly one hour infusion patient paclitaxel/platinum refractory stage III IV ovarian cancer . II . Evaluate safety paclitaxel patient population . III . Assess overall survival patient . IV . Assess quality life patient . OUTLINE : This multicenter , open label , nonrandomized study . Patients administer paclitaxel one hour IV infusion every 7 day . Each cycle consist four week . Treatment may delay 2 week limit number interruption patient may experience . Patients receive paclitaxel weekly disease progression unacceptable toxicity . Treatment assess every 3 cycle one year every 6 month thereafter study . Quality life assess every cycle first 6 cycle , every 3 cycle thereafter . Patients follow every 3 month survival . PROJECTED ACCRUAL : There 100 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV ovarian cancer refractory initial chemotherapy regimen include platinum agent plus paclitaxel Epithelial ovarian cancer Primary carcinoma peritoneum Fallopian tube cancer Initial response platinum paclitaxel must one following : Progression stable disease Response last less 3 month Response last least 3 month , retreat agent ( combination single agent ) disease refractory Measurable evaluable disease Evaluable disease define : CA125 least 100 units/mL AND CA125 level must least doubled baseline determination PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : No New York Heart Association Class III IV heart disease No myocardial infarction within last 6 month No congestive heart failure No unstable angina No clinically significant pericardial effusion arrhythmia Neurology : No current peripheral neuropathy etiology great grade 1 Other : No active serious infection serious underlie medical condition No prior significant allergic reaction drug contain Cremophor , teniposide , cyclosporin , vitamin K Not pregnant nursing Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since immunotherapy No concurrent immunotherapy Chemotherapy : Prior paclitaxel treatment must administer 3 week great schedule No prior chemotherapy besides platinum paclitaxel At least 3 week since acceptable chemotherapy Endocrine therapy : At least 3 week since hormonal therapy No concurrent hormonal therapy Radiotherapy : At least 3 week since radiotherapy No prior radiation great 30 % bone marrow Surgery : At least 3 week since major surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2001</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>